Literature DB >> 9169356

Resistance to bone resorbing effects of PTH in black women.

F Cosman1, D C Morgan, J W Nieves, V Shen, M M Luckey, D W Dempster, R Lindsay, M Parisien.   

Abstract

Black women have a lower incidence of vertebral and hip fractures than white women, possibly due to differences in skeletal and mineral metabolism. One suggested mechanism is that blacks have decreased skeletal sensitivity to parathyroid hormone (PTH). To test this hypothesis, we infused h(1-34)PTH in healthy premenopausal black (n = 15) and white (n = 18) women over 24 h and measured serum and urine indices of bone turnover and calcium metabolism throughout the infusion. At baseline, the mean 25-hydroxyvitamin D (25(OH)D) concentration was significantly lower in black women (46%). There were also nearly significant trends toward higher PTH and lower urinary calcium and pyridinoline levels in black women. During infusion, there were no racial differences in the mean (1-34)PTH levels achieved or in resultant elevations of serum calcium or 1,25-dihydroxyvitamin D (1,25(OH)2D) levels. Endogenous parathyroid suppression (measured by (1-84)PTH levels) was also similar between blacks and whites. There was an initial decline in urinary calcium/creatinine in both groups with a greater reduction in black women early in the infusion period (p < 0.05 at 8 h). Furthermore, blacks had lower levels of urinary calcium/creatinine throughout the infusion (p < 0.05 group difference). Bone formation markers (carboxy-terminal propeptide of type I procollagen and osteocalcin) decreased within 8 h and continued to decline throughout the infusion with no distinguishable racial differences (p < 0.05 time trend for both). The most dramatic difference between black and white women in response to PTH infusion was represented by the bone resorption markers. Three separate metabolites of bone resorption (cross-linked N-telopeptide of type I collagen, cross-linked C-telopeptide of type I collagen, and free pyridinoline) all showed substantially greater elevations in white (mean peak increments 399, 725, and 43%) compared with black women (mean peak increments 317, 369, and 17%) during the infusion (p < 0.05 group differences for all three variables). These data strongly suggest that blacks have decreased skeletal sensitivity to the acute resorptive effects of increased PTH. This finding indicates that calcium homeostasis may be accomplished in blacks (during times of relative calcium deficiency) by greater conservation of calcium from nonskeletal sources (most likely renal) with relative preservation of skeletal tissue. These differences in calcium economy could account, at least in part, for the increased bone mass and lower incidence of osteoporotic fractures in black women.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9169356     DOI: 10.1359/jbmr.1997.12.6.958

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  62 in total

1.  Racial differences in postprandial mineral ion handling in health and in chronic kidney disease.

Authors:  Orlando M Gutiérrez; Tamara Isakova; Kelsey Smith; Michael Epstein; Neha Patel; Myles Wolf
Journal:  Nephrol Dial Transplant       Date:  2010-06-07       Impact factor: 5.992

2.  Demographic, dietary, and serum factors and parathyroid hormone in the National Health and Nutrition Examination Survey.

Authors:  J M Paik; W R Farwell; E N Taylor
Journal:  Osteoporos Int       Date:  2011-09-20       Impact factor: 4.507

3.  The association of serum 25-hydroxyvitamin D with indicators of bone quality in men of Caucasian and African ancestry.

Authors:  K E Barbour; J M Zmuda; M J Horwitz; E S Strotmeyer; R Boudreau; R W Evans; K E Ensrud; C L Gordon; M A Petit; A L Patrick; J A Cauley
Journal:  Osteoporos Int       Date:  2010-11-23       Impact factor: 4.507

4.  Generalized bone loss as a predictor of three-year radiographic damage in African American patients with recent-onset rheumatoid arthritis.

Authors:  Jie Zhang; David T Redden; Gerald McGwin; Leigh F Callahan; Edwin A Smith; Graciela S Alarcón; Larry W Moreland; Désirée M van der Heijde; Elizabeth E Brown; Donna K Arnett; Ted R Mikuls; S Louis Bridges
Journal:  Arthritis Rheum       Date:  2010-08

Review 5.  Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease.

Authors:  Ziad Massy; Tilman Drueke
Journal:  J Nephrol       Date:  2017-04-12       Impact factor: 3.902

6.  Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial.

Authors:  Kimmie Ng; Jamil B Scott; Bettina F Drake; Andrew T Chan; Bruce W Hollis; Paulette D Chandler; Gary G Bennett; Edward L Giovannucci; Elizabeth Gonzalez-Suarez; Jeffrey A Meyerhardt; Karen M Emmons; Charles S Fuchs
Journal:  Am J Clin Nutr       Date:  2013-12-24       Impact factor: 7.045

Review 7.  The uncertain significance of low vitamin D levels in African descent populations: a review of the bone and cardiometabolic literature.

Authors:  Michelle Y O'Connor; Caroline K Thoreson; Natalie L M Ramsey; Madia Ricks; Anne E Sumner
Journal:  Prog Cardiovasc Dis       Date:  2013 Nov-Dec       Impact factor: 8.194

8.  Serum 25-hydroxyvitamin D and bone mineral density in a racially and ethnically diverse group of men.

Authors:  Marian T Hannan; Heather J Litman; Andre B Araujo; Christine E McLennan; Robert R McLean; John B McKinlay; Tai C Chen; Michael F Holick
Journal:  J Clin Endocrinol Metab       Date:  2007-11-06       Impact factor: 5.958

9.  Prevalence of CKD-MBD in pre-dialysis patients using biochemical markers in Enugu, South-East Nigeria.

Authors:  Julius U Okoye; Ejikeme B Arodiwe; Ifeoma I Ulasi; Chinwuba K Ijoma; Obinna D Onodugo
Journal:  Afr Health Sci       Date:  2015-09       Impact factor: 0.927

10.  Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis.

Authors:  Julia J Scialla; Rulan S Parekh; Joseph A Eustace; Brad C Astor; Laura Plantinga; Bernard G Jaar; Tariq Shafi; Josef Coresh; Neil R Powe; Michal L Melamed
Journal:  Am J Nephrol       Date:  2015-08-20       Impact factor: 3.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.